NeurAxon, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 34

NeurAxon, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “NeurAxon, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NeurAxon, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of NeurAxon, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of NeurAxon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the NeurAxon, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NeurAxon, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of NeurAxon, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the NeurAxon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with NeurAxon, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of NeurAxon, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
NeurAxon, Inc. Snapshot
NeurAxon, Inc. Overview
Key Information
Key Facts
NeurAxon, Inc. – Research and Development Overview
Key Therapeutic Areas
NeurAxon, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
NeurAxon, Inc. – Pipeline Products Glance
NeurAxon, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
NeurAxon, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
NeurAxon, Inc. – Drug Profiles
NXN-188
Product Description
Mechanism of Action
R&D Progress
NXN-462
Product Description
Mechanism of Action
R&D Progress
nNOS/iNOS
Product Description
Mechanism of Action
R&D Progress
nNOS/NET
Product Description
Mechanism of Action
R&D Progress
nNOS/Opiate
Product Description
Mechanism of Action
R&D Progress
NeurAxon, Inc. – Pipeline Analysis
NeurAxon, Inc. – Pipeline Products by Therapeutic Class
NeurAxon, Inc. Pipeline Products By Target
NeurAxon, Inc. – Pipeline Products by Route of Administration
NeurAxon, Inc. – Pipeline Products by Molecule Type
NeurAxon, Inc. – Recent Pipeline Updates
NeurAxon, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 31, 2010: NeurAxon Reports NXN-188 Phase II Data Demonstrates Efficacy In Acute Migraine
Oct 27, 2008: NeurAxon's NXN-188 Names One Of 10 Most Promising Neuroscience Projects
Sep 05, 2008: NeurAxon’s NXN-188 Demonstrates Pain Relief In Migraine with Aura
Aug 14, 2007: NeurAxon Announces Positive Phase 1 Trial Data On NXN-188 For Migraine
Financial Deals Landscape
NeurAxon, Inc., Deals Summary, 2004 to 2010
NeurAxon, Inc. Detailed Deal Summary
Venture Financing
NeurAxon Secures $8.75 Million In Convertible Debenture Financing
NeurAxon Secures $32 Million In Series B Venture Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Commercial And Military Flight Simulation - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• The Worldwide Industry & Market Opportunities and forecasts to 2014 for Microwaves Global Military & Space-Related Systems
• International Military and Government Helicopter Survey